Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Rev Epidemiol Sante Publique ; 65(6): 419-426, 2017 Nov.
Artigo em Francês | MEDLINE | ID: mdl-29066256

RESUMO

BACKGROUND: Mortality among TB/HIV co-infected patients remains high in Africa. The study aimed to estimate survival and associated factors in a cohort of TB/HIV co-infected patients who started tuberculosis treatment during the Ebola outbreak in Conakry, Guinea. METHODS: A prospective cohort study was conducted from April 2014 to December 2015. TB patients with HIV co-infection were enrolled at the University Hospital of Conakry. Survival and risk factors were analyzed according to Kaplan-Meier's method, log-rank test and Cox's regression. RESULTS: Data from 573 patients were analyzed. From these, 86 (15.0%) died before the end of treatment, 52% occurring within eight weeks of treatment onset. Survival at 4, 12 and 24 weeks after the beginning of the TB treatment was 92%, 86% and 83%, respectively. Independent risk factors associated with death were in the cell CD4 <200 cells/mm3 [adjusted hazard ratio (AHR): 2.25; 95% CI (confidence intervals): 1.16-4.37], opportunistic infections other than TB [AHR: 2.89; 95% CI: 1.39-6.02], and comorbidities [AHR: 4.12; 95% CI: 2.10-8.10]. An increase of one unit in hemoglobin [AHR: 0.81; 95% CI: 0.75-0.91] was protective of death. CONCLUSION: TB/HIV co-infected patients had a higher fatality rate during treatment of tuberculosis. Prevention of opportunistic infections, anemia and proper management of tuberculosis treatment in early comorbidities may improve survival for TB/HIV co-infected patients in restoring immune function.


Assuntos
Coinfecção/mortalidade , Coinfecção/terapia , Infecções por HIV/mortalidade , Infecções por HIV/terapia , Doença pelo Vírus Ebola/epidemiologia , Tuberculose/mortalidade , Tuberculose/terapia , Adolescente , Adulto , Antituberculosos/uso terapêutico , Causas de Morte , Estudos de Coortes , Comorbidade , Surtos de Doenças , Epidemias , Feminino , Guiné/epidemiologia , HIV , Infecções por HIV/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Mortalidade , Fatores de Risco , Resultado do Tratamento , Tuberculose/complicações , Adulto Jovem
2.
J Med Entomol ; 54(3): 677-681, 2017 05 01.
Artigo em Inglês | MEDLINE | ID: mdl-28399224

RESUMO

Insecticide resistance is one of the primary threats to the recent gains in malaria control. This is especially true in Guinea, where long-lasting insecticidal nets are currently the primary vector control intervention. To better inform the national malaria control program on the current status of insecticide resistance in Guinea, resistance bioassays were conducted, using Anopheles gambiae s.l. Giles, in three sites. Molecular analyses were also done on An. gambiae s.l. to determine the species and find whether the target-site mutations kdr and Ace1R were present. Susceptibility tests revealed resistance to DDT and pyrethroids, although mosquitoes were susceptible to deltamethrin in two of the three sites tested. Mosquitoes were susceptible to bendiocarb, except in Kissidougou, Guinea. The kdr-west mutation was widespread and the frequency was 60% or more in all sites. However, the Ace1R mutation was present in low levels. Insecticide susceptibility should continue to be monitored in Guinea to ensure insecticide-based vector control methods remain effective.


Assuntos
Anopheles/fisiologia , Resistência a Inseticidas , Inseticidas/farmacologia , Animais , Anopheles/genética , Feminino , Marcadores Genéticos , Guiné , Proteínas de Insetos/genética , Proteínas de Insetos/metabolismo , Controle de Mosquitos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA